338 related articles for article (PubMed ID: 24275248)
1. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
2. Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.
El-Sayed S; Metwally K; El-Shanawani AA; Abdel-Aziz LM; El-Rashedy AA; Soliman MES; Quattrini L; Coviello V; la Motta C
Bioorg Med Chem Lett; 2017 Oct; 27(20):4760-4764. PubMed ID: 28935265
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of rhodanine derivatives as aldose reductase inhibitors.
Agrawal YP; Agrawal MY; Gupta AK
Chem Biol Drug Des; 2015 Feb; 85(2):172-80. PubMed ID: 24903533
[TBL] [Abstract][Full Text] [Related]
4. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors.
Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M
Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328
[TBL] [Abstract][Full Text] [Related]
5. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
6. 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
Kato A; Kobayashi K; Narukawa K; Minoshima Y; Adachi I; Hirono S; Nash RJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5630-3. PubMed ID: 20805028
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives.
Celestina SK; Sundaram K; Ravi S
Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051
[TBL] [Abstract][Full Text] [Related]
8. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C
J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461
[TBL] [Abstract][Full Text] [Related]
9. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
[TBL] [Abstract][Full Text] [Related]
10. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
Gu J; Wang JJ; Yan J; Cui CF; Wu WH; Li L; Wang ZS; Yu M; Gao N; Liu L; Ouyang DS
J Ethnopharmacol; 2011 Jan; 133(1):6-13. PubMed ID: 20817083
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition effect of epalrestat on rat lens osmotic expansion].
Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
Maccari R; Vitale RM; Ottanà R; Rocchiccioli M; Marrazzo A; Cardile V; Graziano AC; Amodeo P; Mura U; Del Corso A
Eur J Med Chem; 2014 Jun; 81():1-14. PubMed ID: 24819954
[TBL] [Abstract][Full Text] [Related]
15. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors.
Maccari R; Del Corso A; Giglio M; Moschini R; Mura U; Ottanà R
Bioorg Med Chem Lett; 2011 Jan; 21(1):200-3. PubMed ID: 21129963
[TBL] [Abstract][Full Text] [Related]
17. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.
Lee YS; Chen Z; Kador PF
Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011
[TBL] [Abstract][Full Text] [Related]
19. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
20. Phenolic marine natural products as aldose reductase inhibitors.
Manzanaro S; Salva J; de la Fuente JA
J Nat Prod; 2006 Oct; 69(10):1485-7. PubMed ID: 17067167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
